MedDRA preferred term · several organs failing
Multiple organ dysfunction syndrome: adverse event reports recording this term
27,530 reports to FDA record it, 2004–2026; 0.1% of the database.
- 27,530
- reports recording the term
- 0.1% of all reports
- 3,181
- reports, 12 months to June 2026
- 2,591 in the 12 months before
- 99.9%
- marked serious by the reporter
- 57.4% across all reports
- 79.2%
- record death among outcomes, as reported
- 9.1% across all reports
"Multiple organ dysfunction syndrome" (in plain words, several organs failing) is a MedDRA preferred term recorded in 27,530 adverse event reports received by FDA, 0.1% of the database, from March 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.
3,181 reports recorded it in the 12 months to June 2026, up 23% from 2,591 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 99.9% are marked serious, 79.2% include death among the outcomes and 58.5% include hospitalisation, as reported.
The drugs listed most often as suspect products in those reports are Tacrolimus, Mycophenolate mofetil and Cyclophosphamide. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
Drugs listed as suspect products in these reports
| Drug | Class | Reports with this term | Share of the drug's own reports |
|---|---|---|---|
| Tacrolimus | Calcineurin inhibitor immunosuppressant | 1,952 | 2.1% |
| Mycophenolate mofetil | Antimetabolite immunosuppressant | 1,724 | 2.1% |
| Cyclophosphamide | Alkylating drug | 1,620 | 1.1% |
| Prednisone | Corticosteroid | 1,596 | 0.9% |
| Dexamethasone | Corticosteroid | 1,371 | 1.1% |
| Methylprednisolone | Corticosteroid | 1,262 | 2.5% |
| Rituximab | CD20-directed cytolytic antibody | 1,255 | 0.8% |
| Methotrexate | Folate analog metabolic inhibitor | 1,239 | 0.6% |
| Prednisolone | Corticosteroid | 1,177 | 1.3% |
| Etoposide | Topoisomerase inhibitor | 858 | 1.4% |
| Cytarabine | Nucleoside metabolic inhibitor | 746 | 1.5% |
| Acetaminophen | Nonsteroidal anti-inflammatory drug | 725 | 0.8% |
| Cyclosporine | Calcineurin inhibitor immunosuppressant | 691 | 1.8% |
| Meropenem | Penem antibacterial | 681 | 4.4% |
| Metformin | Biguanide | 656 | 1% |
| Vincristine | — | 630 | 1.1% |
| Vancomycin | Glycopeptide antibacterial | 619 | 2% |
| Allopurinol | Xanthine oxidase inhibitor | 584 | 2.6% |
| Metronidazole | Nitroimidazole antimicrobial | 572 | 2.4% |
| Doxorubicin | Anthracycline topoisomerase inhibitor | 552 | 1% |
| Fludarabine | Nucleoside metabolic inhibitor | 533 | 2.6% |
| Ceftriaxone | Cephalosporin antibacterial | 434 | 2.5% |
| Voriconazole | Azole antifungal | 423 | 3.1% |
| Lansoprazole | Proton pump inhibitor | 421 | 1.6% |
| Carboplatin | Platinum-based drug | 409 | 0.4% |
Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
By pharmacologic class
| Class | Reports with this term | Share of class reports | Median drug in class |
|---|---|---|---|
| Corticosteroid | 6,826 | 0.8% | 0% |
| Calcineurin inhibitor immunosuppressant | 2,842 | 1.4% | 0% |
| Alkylating drug | 2,750 | 1.1% | 0.2% |
| Nucleoside metabolic inhibitor | 2,423 | 0.8% | 0.5% |
| Antimetabolite immunosuppressant | 2,142 | 1.8% | 1.4% |
| Nonsteroidal anti-inflammatory drug | 1,646 | 0.3% | 0% |
| Folate analog metabolic inhibitor | 1,497 | 0.5% | 0.3% |
| Proton pump inhibitor | 1,442 | 0.3% | 0.1% |
| Kinase inhibitor | 1,413 | 0.2% | 0.1% |
| CD20-directed cytolytic antibody | 1,371 | 0.4% | 0.1% |
Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.
Patients in these reports
Patient age
Patient sex
Grey bar: all 20,646,523 reports in the database. 29.1% of these reports give the United States as the country.
Questions about "Multiple organ dysfunction syndrome"
What does "Multiple organ dysfunction syndrome" mean in an adverse event report?
In plain language: several organs failing. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.
How many reports record multiple organ dysfunction syndrome?
27,530 reports through June 2026 (0.1% of all reports), 3,181 of them in the latest 12 months.
Which drugs appear most often in these reports?
Tacrolimus (1,952), Mycophenolate mofetil (1,724), Cyclophosphamide (1,620), Prednisone (1,596) and Dexamethasone (1,371). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Does a drug appearing here mean it was responsible for this reaction?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
I have this symptom. What should I do?
This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.